Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label evaluation of basiliximab maintenance in ulcerative colitis
2006-006319-54Phase 2Terminated
- Sponsor
- Cerimon Pharmaceuticals, Inc.
- Start
- Dec 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of basiliximab in autoimmune colitis, sponsored by Cerimon Pharmaceuticals, Inc. Primary endpoint: Primary safety endpoint. Started Dec 2006; status: terminated.
02
Drugs
basiliximab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2006-006319-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006319-54.